These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 27762202)

  • 21. Optimisation of assessment for rheumatic diseases in clinical trials, observational studies and routine clinical care.
    Pincus T; Braun J; Kavanaugh A; Smolen JS
    Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-1. PubMed ID: 25365080
    [No Abstract]   [Full Text] [Related]  

  • 22. Optimisation of rheumatic disease assessments in clinical trials, clinical care, and long-term databases.
    Landewé RB; van der Heijde D
    Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-2-6. PubMed ID: 25365081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RHEUMDOC: a one-page RHEUMatology DOCtor form with four physician global estimates for overall status, inflammation, damage, and symptoms based on neither inflammation nor damage.
    Bergman MJ; Castrejón I; Pincus T
    Bull Hosp Jt Dis (2013); 2014; 72(2):142-7. PubMed ID: 25150341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Computer Assisted Management in Early Rheumatoid Arthritis programme tool used in the CAMERA-I and CAMERA-II studies.
    Jacobs JW;
    Clin Exp Rheumatol; 2016; 34(5 Suppl 101):S69-S72. PubMed ID: 27762192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The History of Patient-Reported Outcomes in Rheumatology.
    Callahan LF
    Rheum Dis Clin North Am; 2016 May; 42(2):205-17. PubMed ID: 27133485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Are patient questionnaire scores as "scientific" as laboratory tests for rheumatology clinical care?
    Pincus T
    Bull NYU Hosp Jt Dis; 2010; 68(2):130-9. PubMed ID: 20632989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Computer-aided treat to target (T2T) Approach for the Rheumatology Patient.
    Gogia SB; Malaviya A
    Stud Health Technol Inform; 2013; 192():937. PubMed ID: 23920711
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RADAI-5 to monitor rheumatoid arthritis.
    Leeb BF; Haindl PM; Brezinschek HP; Nothnagl T; Rintelen B
    Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-55-8. PubMed ID: 25365090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The National Data Bank for Rheumatic Diseases (NDB).
    Michaud K
    Clin Exp Rheumatol; 2016; 34(5 Suppl 101):S100-S101. PubMed ID: 27762196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The international classification for functioning, disability and health. A challenge and a need for rheumatology.
    Boonen A; Rasker JJ; Stucki G
    Clin Rheumatol; 2007 Nov; 26(11):1803-8. PubMed ID: 17558464
    [No Abstract]   [Full Text] [Related]  

  • 31. Using Health Information Technology to Support Use of Patient-Reported Outcomes in Rheumatology.
    Gandrup J; Yazdany J
    Rheum Dis Clin North Am; 2019 May; 45(2):257-273. PubMed ID: 30952397
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MDHAQ/RAPID3 can provide a roadmap or agenda for all rheumatology visits when the entire MDHAQ is completed at all patient visits and reviewed by the doctor before the encounter.
    Pincus T; Skummer PT; Grisanti MT; Castrejón I; Yazici Y
    Bull NYU Hosp Jt Dis; 2012; 70(3):177-86. PubMed ID: 23259625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Corrona US registry of rheumatic and autoimmune diseases.
    Kremer JM
    Clin Exp Rheumatol; 2016; 34(5 Suppl 101):S96-S99. PubMed ID: 27762197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Swedish Rheumatology Quality Register: optimisation of rheumatic disease assessments using register-enriched data.
    Eriksson JK; Askling J; Arkema EV
    Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-147-9. PubMed ID: 25365105
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MDHAQ/RAPID3 scores: quantitative patient history data in a standardized "scientific" format for optimal assessment of patient status and quality of care in rheumatic diseases.
    Pincus T; Castrejón I
    Bull NYU Hosp Jt Dis; 2011; 69(3):201-14. PubMed ID: 22035430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Why is methotrexate the first selection in disease-modifying antirheumatic drug therapy? Comment on the article by Wolfe et al.
    Caballero-Uribe CV
    Arthritis Care Res; 1999 Apr; 12(2):152. PubMed ID: 10513503
    [No Abstract]   [Full Text] [Related]  

  • 37. Introducing new tools for assessment of parent- and child-reported outcomes in paediatric rheumatology practice: a work in progress.
    Filocamo G; Consolaro A; Ferrari C; Ravelli A
    Clin Exp Rheumatol; 2013; 31(6):964-8. PubMed ID: 23981398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The treatment of enthesitis in psoriatic arthritis.
    Kumar N; Kay LJ; Walker DJ
    J Rheumatol; 2004 Nov; 31(11):2311-2; author reply 2312-3. PubMed ID: 15536671
    [No Abstract]   [Full Text] [Related]  

  • 39. RAPID3-an index of physical function, pain, and global status as "vital signs" to improve care for people with chronic rheumatic diseases.
    Pincus T; Bergman MJ; Yazici Y
    Bull NYU Hosp Jt Dis; 2009; 67(2):211-25. PubMed ID: 19583557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Status versus changes, onset of action, and sustainability--how do we define and present these concepts in clinical trial reports in rheumatology?
    Dougados M
    Bull NYU Hosp Jt Dis; 2011; 69(2):111-5. PubMed ID: 22035389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.